BioCryst Pharmaceuticals Inc. (BCRX) now expects final results from a phase I healthy volunteer study of BCX7353, which is being developed for the treatment of hereditary angioedema, in the fourth quarter. The results were initially expected to be announced this quarter, and the delay is due to the addition of a 14 day treatment cohort to the study.